Abstract
Acute administration of gepirone, a 5-HT1A agonist, caused a dose dependent (1–10 mg/kg, IP) reduction in the locomotor activity (open and closed arms) of rats tested in the elevated plus-maze. However, rats housed in individual cages and submitted to chronic treatment with gepirone (10 mg/kg PO) showed a marked increase in the percentages of number and time spent in the open arms as compared to controls. These results are compatible with the idea that the antiaversive effect due to long-term treatment with 5-HT1A agonists is the result of a progressive desensitization of the somatodendritic 5-HT autoreceptor with the consequent recovery of firing rate of 5-HT neurons along with an activation of normosensitive postsynaptic 5-HT neurons. Ketanserin caused a biphasic effects on the exploratory behavior of rats in the plus-maze. The lower dose (0.5 mg/kg) decreased the aversion to the open arms and the higher dose (1.0 mg/kg) caused an unspecific decrease in the overall activity of the animals. Ketanserin is supposed to have antagonistic action on 5-HT2 and on α-adrenergic receptors. As prazosin (0.5–1.0 mg/kg), an α-adrenergic receptor blocker, did not present any significant effect in the present work it is suggested that the effects of the lower dose of ketanserin was due to its high antagonistic action on 5-HT2 receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Backus LI, Sharp T, Grahame-Smith DG (1990) Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol 100:793–799
Blier P, De Montigny C (1987) Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1:470–480
Blier P, De Montigny C, Chaput Y (1987) Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J Clin Psychopharmacol 7:24–35
Bradley PB, Engel G, Fenjiuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylencharane BP, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576
Celeumans DLS, Hoppenbrowers MLJA, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a serotonin antagonist in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18:303–305
Colpaert FC, Meert TF, Niemegeers CJE, Janssen PAJ (1985) Behavioral and 5-HT antagonist properties of ritanserin: a pure and selective antagonist of LSD discrimination in the rat. Psychopharmacology 86:45–54
Csanolosi I, Schweizer E, Warren GC, Rickels K (1987) Gepirone in anxiety: a pilot study. J Clin Psychopharmacol 7:31–33
Critchley MAE, Handley SL (1987) Effects in the +-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology 93:502–506
Deakin JKW (1989) 5-HT receptor subtypes in depression. In: Bevan P, Cools AR, Archer T (eds) Behavioral pharmacology of 5-HT. Lawrence Erlbaum, Hillsdale, New Jersey, pp 179–204
Eison AS, Eison MS, Stanley M, Riblet LA (1986) Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 24:701–707
Engel JA, Hjorth S, Svensson K, Carlson A, Liljequist S (1984) Anticonflict effect of the putative serotonin agonist 8-hydroxy-2-(DL-n-propylamino)-tetralin(8-OH-DPAT). Eur J Pharmacol 105:385–388
Fozard JR (1987) 5-HT; the enigma variations. TIPS 8:501–505
Gehlbach G, Vander Maelen CP (1985) The nonbenzodiazepinic antidepressant-anxiolytic candidate, gepirone, inhibits serotonergic dorsal raphe neurons in the rat midbrain slice. Soc Neurosci Abstr 11:60.11
Graeff FG (1990) Brain defense systems and anxiety. In: Roth M, Burrows GD, Noyes R (eds) Handbook of anxiety, vol 3. Elsevier, Amsterdam, pp 307–354
Gray JA (1987) The psychology of fear and stress. Cambridge University Press, Cambridge
Hoyer D (1988) Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res 8:59–81
Iversen SD (1984) 5-HT and anxiety. Neuropharmacology 23:1533–1560
Jenck F, Broekkamp CLE, Van Delft AML (1989) Effects of serotonin receptor antagonists on PAG stimulation induced aversion: different contributions of 5-HT1, 5-HT2 and 5-HT3 receptors. Psychopharmacology 97:489–495
Kostowski W, Plazmik A, Stefanski R (1989) Intra-hippocampal buspirone in animal models of anxiety. Eur J Pharmacol 168:393–396
Leysen JE, Awonters F, Kennis L, Laduron PH, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R 41468, a novel antagonist at 5-HT2 receptors. Life Sci 28:1015–1022
McCall RB, Schuette MR (1984) Evidence for an alpha 1 receptor-mediated central sympathoinhibitory action of ketanserin. J Pharmacol Exp Ther 228:704–710
McMillen BA, Scott SM, Williams HL, Saghera MK (1987) Effects of gepirone, an arylpiperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission. Naunyn Schmiedeberg's Arch Pharmacol 335:454–461
Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205–230
Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525–529
Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in the elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167
Peroutka SJC (1985) Selective labeling of 5-HT1A and 5-HT1B binding sites in bovine brain. Brain Res 344:167–171
Söderpalm S, Hjorth S, Engel JA (1989) Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test. Pharmacol Biochem Behav 32:259–265
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Motta, V., Maisonnette, S., Morato, S. et al. Effects of blockade of 5-HT2 receptors and activation of 5-HT1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology 107, 135–139 (1992). https://doi.org/10.1007/BF02244978
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244978